These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 17252538)
1. Differential retention of alpha-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells. Ni J; Pang ST; Yeh S Prostate; 2007 Apr; 67(5):463-71. PubMed ID: 17252538 [TBL] [Abstract][Full Text] [Related]
2. The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3. Yin Y; Ni J; Chen M; DiMaggio MA; Guo Y; Yeh S Clin Cancer Res; 2007 Apr; 13(7):2271-80. PubMed ID: 17404112 [TBL] [Abstract][Full Text] [Related]
3. Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway. Ni J; Wen X; Yao J; Chang HC; Yin Y; Zhang M; Xie S; Chen M; Simons B; Chang P; di Sant'Agnese A; Messing EM; Yeh S Cancer Res; 2005 Nov; 65(21):9807-16. PubMed ID: 16267002 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer. Ni J; Mai T; Pang ST; Haque I; Huang K; DiMaggio MA; Xie S; James NS; Kasi D; Chemler SR; Yeh S Clin Cancer Res; 2009 Feb; 15(3):898-906. PubMed ID: 19188160 [TBL] [Abstract][Full Text] [Related]
5. RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness. Zhang M; Altuwaijri S; Yeh S Oncogene; 2004 Apr; 23(17):3080-8. PubMed ID: 15048090 [TBL] [Abstract][Full Text] [Related]
6. Alpha-vitamin E derivative, RRR-alpha-tocopheryloxybutyric acid inhibits the proliferation of prostate cancer cells. Chang E; Ni J; Yin Y; Lin CC; Chang P; James NS; Chemler SR; Yeh S Asian J Androl; 2007 Jan; 9(1):31-9. PubMed ID: 17187157 [TBL] [Abstract][Full Text] [Related]
7. Agents used for chemoprevention of prostate cancer may influence PSA secretion independently of cell growth in the LNCaP model of human prostate cancer progression. Peternac D; Klima I; Cecchini MG; Schwaninger R; Studer UE; Thalmann GN Prostate; 2008 Sep; 68(12):1307-18. PubMed ID: 18512728 [TBL] [Abstract][Full Text] [Related]
8. CCR2 expression correlates with prostate cancer progression. Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598 [TBL] [Abstract][Full Text] [Related]
9. RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects. Yin Y; Ni J; Chen M; Guo Y; Yeh S Clin Cancer Res; 2009 Jan; 15(1):190-200. PubMed ID: 19118046 [TBL] [Abstract][Full Text] [Related]
10. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. Crispen PL; Uzzo RG; Golovine K; Makhov P; Pollack A; Horwitz EM; Greenberg RE; Kolenko VM Prostate; 2007 May; 67(6):582-90. PubMed ID: 17262802 [TBL] [Abstract][Full Text] [Related]
11. Differential response of human ovarian cancer cells to induction of apoptosis by vitamin E Succinate and vitamin E analogue, alpha-TEA. Anderson K; Simmons-Menchaca M; Lawson KA; Atkinson J; Sanders BG; Kline K Cancer Res; 2004 Jun; 64(12):4263-9. PubMed ID: 15205340 [TBL] [Abstract][Full Text] [Related]
12. Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. Koike H; Sekine Y; Kamiya M; Nakazato H; Suzuki K Urology; 2008 Dec; 72(6):1229-33. PubMed ID: 18336887 [TBL] [Abstract][Full Text] [Related]
13. Critical roles for JNK, c-Jun, and Fas/FasL-Signaling in vitamin E analog-induced apoptosis in human prostate cancer cells. Jia L; Yu W; Wang P; Li J; Sanders BG; Kline K Prostate; 2008 Mar; 68(4):427-41. PubMed ID: 18196534 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of 5 alpha-reductase type 1 increases sensitivity of prostate cancer cells to low concentrations of testosterone. Thomas LN; Douglas RC; Rittmaster RS; Too CK Prostate; 2009 May; 69(6):595-602. PubMed ID: 19125422 [TBL] [Abstract][Full Text] [Related]
15. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3. Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422 [TBL] [Abstract][Full Text] [Related]
16. Tocopherol transfer protein sensitizes prostate cancer cells to vitamin E. Morley S; Thakur V; Danielpour D; Parker R; Arai H; Atkinson J; Barnholtz-Sloan J; Klein E; Manor D J Biol Chem; 2010 Nov; 285(46):35578-89. PubMed ID: 20826775 [TBL] [Abstract][Full Text] [Related]
17. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer. Malinowska K; Cavarretta IT; Susani M; Wrulich OA; Uberall F; Kenner L; Culig Z Prostate; 2009 Jul; 69(10):1109-18. PubMed ID: 19353593 [TBL] [Abstract][Full Text] [Related]
18. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Das S; Roth CP; Wasson LM; Vishwanatha JK Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor. Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333 [TBL] [Abstract][Full Text] [Related]
20. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. Mariani S; Salvatori L; Basciani S; Arizzi M; Franco G; Petrangeli E; Spera G; Gnessi L J Urol; 2006 Jun; 175(6):2072-7; discussion 2077. PubMed ID: 16697805 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]